News

1 2 3 4 9 17 25 33
NEWS

SOTIO Announces Upcoming Poster Presentations at the 2024 SITC Annual Meeting

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November 6 - 10, 2024, in Houston, TX.

NEWS

SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline

  • Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform;
  • Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs;
  • Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million;
NEWS

SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors

  • Novel immunocytokine utilizes dual mechanisms of action to activate immune system to fight solid tumors;
  • Company has received IND and CTA approval to initiate Phase 1 study in the U.S. and Europe.

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced the dosing of the first patient in its Phase 1, first-in-human clinical trial evaluating SOT201, a next-generation PD-1-targeting immunocytokine. The VICTORIA-01 study will evaluate the safety, tolerability and initial efficacy of SOT201 monotherapy for the treatment of advanced solid tumors.